The Child–Pugh classification is one of the commonest and oldest bedside tools utilized in
estimating prognosis in patients with cirrhosis. However, its usage as a risk prediction tool or …

Polymorphisms of genes encoding drug metabolizing enzymes and transporters can
significantly modify pharmacokinetics, and this can be associated with significant differences …

Provides a timely update to a key textbook on human drug metabolism The third edition of
this comprehensive book covers basic concepts of teaching drug metabolism, starting from …

Aims Proton pump inhibitors (PPIs) belong to the most frequently used drugs, also in
patients with cirrhosis. PPIs are extensively metabolized by the liver, but practice guidance …

Patients with chronic liver disease (CLD) are becoming increasingly complex due to the
rising prevalence of multimorbidity and polypharmacy. Medications are often essential to …

Introduction: The global burden of cirrhosis is rising, and clinicians increasingly face the
challenge of safely prescribing medicines for complications of hepatic disease and …

Introduction The presence of liver cirrhosis can have a major impact on pharmacodynamics
and pharmacokinetics, but guidance for prescribing is lacking. Objective The aim of this …

Introduction Patients with cirrhosis are at risk for adverse drug reactions (ADRs) due to
altered pharmacokinetics and pharmacodynamics. We aimed to determine the prevalence of …

As a consequence of the altered hepatic architecture in advanced liver disease, drug
metabolism is modified by changes in pharmacokinetic and pharmacodynamic properties …

Background: In 2005, the European Medicines Agency (EMA) released guidance on
pharmacokinetic studies in patients with hepatic impairment. This guidance describes the …